Results 261 to 270 of about 34,307 (290)
Some of the next articles are maybe not open access.
Enfuvirtide: first fusion inhibitor for treatment of HIV infection
American Journal of Health-System Pharmacy, 2004The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and availability of enfuvirtide are discussed.To date, 20 antiretrovirals have been approved by FDA for the treatment of HIV infection. The recent approval of enfuvirtide offers a new and fourth class of antiretroviral agents called fusion inhibitors.
M Christine, Jamjian, Ian R, McNicholl
openaire +2 more sources
Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide
Journal of Theoretical Biology, 2011Recently, the first drug in a new class of antiretroviral HIV drugs was approved, the fusion inhibitor enfuvirtide. We develop a mathematical model that describes the binding of the virus to T cells. We model the effect of enfuvirtide upon this process using impulsive differential equations.
Lou, Jie, Smith, Robert J
openaire +2 more sources
Peptide HIV fusion inhibitors: modifications and conjugations
Med. Chem. Commun., 2014HIV fusion inhibitors are a group of virus entry preventing drugs aimed at membrane fusion.
Wei Liu +4 more
openaire +1 more source
Enfuvirtide: The first fusion inhibitor for HIV
Practice Nursing, 2005Emma MacFarlane explains the action of a new antiretroviral for HIV and considers the nurse's role in patient education and support
openaire +1 more source
The peptides and peptidomimetics: HIV-1 fusion inhibitors
SCIENTIA SINICA Chimica, 2013The fusion of HIV and target cell membranes is mediated by the transmembrane glycoprotein gp41. HIV-1 fusion inhibitors target gp41 to prevent the virus-cell membrane fusion, thus interrupt the initial steps of viral replication. The first peptide fusion inhibitor (T-20) was approved by the U.S. FDA in 2003. However, the application of T-20 was limited
QiYan JIA, KeLiang LIU, LiFeng CAI
openaire +1 more source
Development of potent and long-acting HIV-1 fusion inhibitors
AIDS, 2016T20 (enfuvirtide) is the first approved HIV entry inhibitor and currently the only viral fusion inhibitor, but its low efficacy and genetic barrier to resistance significantly limit its application, calling for a next-generation drug.On the basis of the M-T hook structure, we recently developed a short-peptide named HP23, which mainly targets the deep ...
Huihui, Chong +3 more
openaire +2 more sources
HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications
Drug Resistance Updates, 2004The increasing prevalence of HIV isolates resistant to one or multiple antiretroviral drugs has fueled the search for new agents that work by novel mechanisms. Enfuvirtide (ENF), licensed in 2002, is the first marketed antiretroviral (ARV) agent that targets viral entry. ENF blocks the virus replication cycle by binding to gp41, a critical component of
Michael D, Miller, Daria J, Hazuda
openaire +2 more sources
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
Journal of the American Academy of Dermatology, 2003Enfuvirtide is the first of a new class of antiretroviral agents for the treatment of HIV-1 infection, called the fusion inhibitors. The most common type of adverse event associated with enfuvirtide treatment is injection site reactions, occurring in up to 98% of patients. Many of these lesions are symptomatic.
Russell A, Ball, Tosca, Kinchelow
openaire +2 more sources
Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors
ChemBioChemSince the membrane fusion step is the last chance to block the virus extracellularly, membrane fusion is an important target for anti‐human immunodeficiency virus (HIV) agents. Previously, the dimeric derivatives of C34, which are contained in the HIV‐1 envelope protein gp41 are found, linked by a disulfide bridge or a pegylated ...
Kohei Tsuji +5 more
openaire +2 more sources
The development of a new fusion inhibitor for the treatment of HIV
2017Since the introduction of combination antiretroviral therapy (ART), there has been a dramatic improvement in the prognosis of people living with HIV. Indeed, data from numerous cohorts now show that for people commenced on ART at high CD4 counts and who are retained in care, life expectancy is similar to matched HIV-negative people.
openaire +2 more sources